Aprea Therapeutics (NASDAQ:APRE) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $20.00 target price on the stock.

Aprea Therapeutics Price Performance

Shares of NASDAQ:APRE opened at $3.34 on Tuesday. The firm has a market capitalization of $18.15 million, a PE ratio of -1.19 and a beta of 0.88. Aprea Therapeutics has a 1 year low of $2.15 and a 1 year high of $8.85. The firm’s 50-day moving average is $3.44 and its two-hundred day moving average is $3.57.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.45 million. Analysts expect that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Bernd R. Seizinger acquired 10,000 shares of the company’s stock in a transaction on Friday, October 11th. The shares were bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now owns 44,730 shares in the company, valued at approximately $119,876.40. This trade represents a 28.79 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total transaction of $29,595.96. Following the completion of the sale, the director now owns 233,651 shares in the company, valued at $1,070,121.58. The trade was a 2.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders purchased 42,290 shares of company stock valued at $165,096 in the last three months. 12.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.